Marksans Pharma

Why is Marksans Pharma Ltd falling/rising?

As of 15-Jun, Marksans Pharma Ltd's stock price is at 249.60, down 1.01%, reflecting a trend reversal after two days of gains and a significant drop in delivery volume. Despite a strong year-to-date performance of 38.55%, the stock faces challenges with limited long-term growth prospects and a high valuation.

As of 15-Jun, Marksans Pharma Ltd's stock price is currently at 249.60, reflecting a decrease of 2.55, or 1.01%. The stock has underperformed its sector by 0.38% today and has experienced a trend reversal, falling after two consecutive days of gains. This decline may be attributed to a decrease in investor participation, as evidenced by a 21.74% drop in delivery volume compared to the 5-day average.<BR><BR>Despite the current price drop, Marksans Pharma has shown strong performance over various periods, with a year-to-date increase of 38.55%, significantly outperforming the Sensex, which has decreased by 10.51% during the same timeframe. The stock has also demonstrated impressive returns over the past three years, rising by 187.52%. However, the stock's long-term growth prospects appear limited, with an annual operating profit growth rate of only 10.60% over the last five years.<BR><BR>Additionally, while the company boasts a high return on equity (ROE) of 15.04% and is net-debt free, it faces challenges due to its relatively expensive valuation, indicated by a price-to-book value of 3.7. The stock's performance over the past year has been negative, with a return of -3.57%, despite a profit increase of 9.8%. This situation, combined with high institutional holdings that have increased by 9.3% over the previous quarter, suggests that while there are positive factors supporting the stock, the recent price decline may be influenced by short-term trading dynamics and concerns over long-term growth potential.

Which are the latest news on Marksans Pharma?

How big is Marksans Pharma?

As of 10th June, Marksans Pharma Ltd has a market capitalization of 11,449.00 Cr, with recent net sales of 2,950.94 Cr and a net profit of 417.90 Cr.

As of 10th June, Marksans Pharma Ltd has a market capitalization of 11,449.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Marksans Pharma reported Net Sales of 2,950.94 Cr and a Net Profit of 417.90 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,466.91 Cr and Total Assets of 3,239.63 Cr.

Who are in the management team of Marksans Pharma?

The management team of Marksans Pharma includes Mark Saldanha (Chairman & Managing Director), Harshavardhan Panigrahi (Company Secretary), and several directors, including Sandra Saldanha and Digant Mahesh Parikh, among others, who oversee the company's governance and strategic direction.

The management team of Marksans Pharma includes the following key members:<BR><BR>1. **Mark Saldanha** - Chairman & Managing Director<BR>2. **Harshavardhan Panigrahi** - Company Secretary & Compliance Officer<BR>3. **Seetharama Raju Buddharaju** - Non-Executive & Independent Director<BR>4. **Sandra Saldanha** - Whole-time Director<BR>5. **Digant Mahesh Parikh** - Non-Executive & Independent Director<BR>6. **Varddhman Vikramaditya Jain** - Whole-time Director<BR>7. **Abhinna Sundar Mohanty** - Non-Executive & Independent Director<BR>8. **Sunny Sharma** - Director<BR>9. **Shailaja Vardhan** - Independent Director<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

Who are the peers of the Marksans Pharma?

Peers of Marksans Pharma include Natco Pharma, Jubilant Pharma, Alembic Pharma, and others. Marksans Pharma has good growth and excellent capital structure, with a 1-year return of -2.98%, while Viyash Scientifi leads with a 26.25% return.

Peers: The peers of Marksans Pharma are Natco Pharma, Jubilant Pharmo, Alembic Pharma, Concord Biotech, Alivus Life, Viyash Scientifi, Shilpa Medicare, Sanofi Consumer, and P & G Health Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, Sanofi Consumer, and P & G Health Ltd, while Good management risk is found at Marksans Pharma. Average management risk is present at Jubilant Pharmo and Viyash Scientifi, while Below Average management risk is noted at Shilpa Medicare. All peers exhibit Below Average growth except for Marksans Pharma, which has Good growth, while the rest show Below Average growth. Excellent capital structure is seen at Natco Pharma, Alembic Pharma, Concord Biotech, Alivus Life, Sanofi Consumer, and P & G Health Ltd, while Marksans Pharma also has Excellent capital structure, and the rest have Average or Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Viyash Scientifi at 26.25%, while the lowest is Concord Biotech at -37.75%. Marksans Pharma's 1-year return is -2.98%, which is higher than Concord Biotech but lower than Viyash Scientifi. Additionally, Concord Biotech and Shilpa Medicare have negative six-month returns.

What does Marksans Pharma do?

Marksans Pharma Ltd is a small-cap company involved in the research, manufacture, marketing, and sale of pharmaceutical formulations. As of March 2026, it reported net sales of ₹856 Cr and a net profit of ₹148 Cr.

Overview:<BR>Marksans Pharma Ltd is engaged in the research, manufacture, marketing, and sale of pharmaceutical formulations within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History:<BR>Marksans Pharma Limited was originally incorporated as Tasc Pharmaceuticals Limited in April 1982. The company underwent a name change following a Scheme of Amalgamation, officially becoming Marksans Pharma Limited on October 10, 2005. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 856 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 148 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 11,449 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 27.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.32%<BR>- Debt Equity: -0.21<BR>- Return on Equity: 13.82%<BR>- Price to Book: 3.79<BR><BR>Contact Details:<BR>Address: 11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W) Mumbai Maharashtra : 400053<BR>Tel: 91-22-40012000<BR>Email: companysecretary@marksanspharma.com<BR>Website: http://www.marksanspharma.com

Should I buy, sell or hold Marksans Pharma Ltd?

Are Marksans Pharma Ltd latest results good or bad?

Marksans Pharma Ltd's latest Q4 FY26 results are very good, with a net profit of ₹148.13 crores (up 63.59% year-on-year) and revenue of ₹856.11 crores (up 20.84%). The operating margin improved to 22.83%, indicating strong business momentum and effective cost management.

Marksans Pharma Ltd's latest results for Q4 FY26 can be considered very good. The company reported a net profit of ₹148.13 crores, reflecting a significant year-on-year increase of 63.59%. Revenue also saw a strong performance, reaching ₹856.11 crores, which is a 20.84% increase compared to the same quarter last year. <BR><BR>Additionally, the operating margin improved to 22.83%, marking the highest level achieved by the company, indicating enhanced operational efficiency. The profit after tax (PAT) margin also expanded to 17.41%, up from 12.81% in the same quarter last year, showcasing improved profitability alongside revenue growth.<BR><BR>Overall, the financial metrics indicate strong business momentum and effective cost management, making the latest results a positive reflection of Marksans Pharma's performance.

When is the next results date for Marksans Pharma Ltd?

The next results date for Marksans Pharma Ltd is 26 May 2026.

The next results date for Marksans Pharma Ltd is scheduled for 26 May 2026.

How has been the historical performance of Marksans Pharma?

Marksans Pharma has shown consistent growth, with net sales increasing from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, alongside rising profits and total assets. Despite a slight decrease in operating profit margin, the company has maintained positive cash flow from operations while investing in growth.

Answer:<BR>The historical performance of Marksans Pharma shows a consistent growth trajectory in key financial metrics over the years.<BR><BR>Breakdown:<BR>Marksans Pharma's net sales have steadily increased from INR 1,134.21 crore in March 2020 to INR 2,622.85 crore in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from INR 1,000.07 crore in March 2019 to INR 2,622.85 crore in March 2025. The company's total expenditure, excluding depreciation, also grew significantly, reaching INR 2,090.16 crore in March 2025, up from INR 941.96 crore in March 2020. Operating profit (PBDIT) has shown a positive trend, increasing from INR 192.25 crore in March 2020 to INR 599.02 crore in March 2025, although the operating profit margin slightly decreased from 21.06% in March 2024 to 20.31% in March 2025. Profit before tax rose from INR 157.17 crore in March 2020 to INR 503.97 crore in March 2025, while profit after tax increased from INR 120.75 crore to INR 382.62 crore over the same period. The company's total assets have also expanded significantly, from INR 902.03 crore in March 2020 to INR 3,239.63 crore in March 2025, indicating robust growth in its financial position. Cash flow from operating activities has remained positive, with INR 206 crore in March 2025, although cash flow from investing activities has been negative, reflecting investments in growth. Overall, Marksans Pharma has demonstrated strong financial performance and growth across multiple dimensions.

Is Marksans Pharma technically bullish or bearish?

As of November 13, 2025, Marksans Pharma's technical trend is mildly bearish, supported by daily moving averages and Bollinger Bands, despite some mixed signals from weekly indicators.

As of 13 November 2025, the technical trend for Marksans Pharma has changed from sideways to mildly bearish. The current stance is bearish, with key indicators driving this assessment including the daily moving averages showing a mildly bearish trend and the Bollinger Bands indicating a mildly bearish position on both weekly and monthly time frames. Although the weekly MACD and KST are mildly bullish, the overall monthly indicators, including MACD and KST, are mildly bearish, reinforcing the bearish sentiment. The RSI on the weekly is bullish but lacks confirmation from the monthly signal, contributing to a mixed outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader context of the stock's performance compared to the Sensex.

Is Marksans Pharma overvalued or undervalued?

As of October 10, 2025, Marksans Pharma is considered overvalued with a PE ratio of 23.52 and a year-to-date decline of 38.65%, contrasting with the Sensex's 5.58% return.

As of 10 October 2025, Marksans Pharma's valuation grade has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE ratio of 23.52, an EV to EBITDA of 15.66, and a PEG ratio of 4.80. Compared to its peers, Marksans Pharma's valuation appears high; for instance, Sun Pharma has a PE ratio of 34.96, while Cipla is more attractively valued at a PE of 23.39.<BR><BR>Given these metrics, Marksans Pharma is overvalued in the current market context. The company's recent stock performance shows a significant decline year-to-date at -38.65%, contrasting sharply with the Sensex return of 5.58% during the same period, further supporting the notion that the stock may not be a favorable investment at this time.

Who are the top shareholders of the Marksans Pharma?

The top shareholders of Marksans Pharma include Mark Saldanha with 43.8%, Orbimed Asia IV Mauritius FVCI Limited at 10.88%, and various foreign institutional investors owning 22.2%. Additionally, mutual funds hold 3.37%, while individual investors account for 25.77% of the shares, with no pledged promoter holdings reported.

The top shareholders of Marksans Pharma include a mix of promoters and institutional investors. The largest shareholder is Mark Saldanha, who holds 43.8% of the company's shares. Other significant shareholders include Orbimed Asia IV Mauritius FVCI Limited, which holds 10.88%, and various foreign institutional investors (FIIs) who collectively own 22.2% of the company through 135 different entities. Additionally, mutual funds hold 3.37% across 9 schemes, while individual investors account for 25.77% of the shareholding. There are no pledged promoter holdings reported.

Has Marksans Pharma declared dividend?

Marksans Pharma Ltd has declared a 60% dividend, amounting to ₹0.6 per share, with an ex-date of September 17, 2024. While the last 6 months showed a price decline of 25.33%, longer-term returns over 1 to 5 years indicate significant growth, particularly in price returns.

Marksans Pharma Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 0.6<BR>- Ex-date: Sep-17-2024<BR><BR>Dividend Yield: 0.23%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.33%, with a dividend return of 0%, resulting in a total return of -25.33%.<BR><BR>Over the past year, the price return was 67.19%, with a dividend return of 0.39%, leading to a total return of 67.58%.<BR><BR>In the 2-year period, the price return was 183.54%, with a dividend return of 0.66%, culminating in a total return of 184.2%.<BR><BR>For the 3-year period, the price return was 452.34%, with a dividend return of 3.27%, resulting in a total return of 455.61%.<BR><BR>In the last 4 years, the price return was 253.48%, with a dividend return of 1.83%, leading to a total return of 255.31%.<BR><BR>Over the past 5 years, the price return was 698.11%, with a dividend return of 4.81%, culminating in a total return of 702.92%.<BR><BR>Overall, Marksans Pharma has declared a substantial dividend, and while the recent 6-month performance shows a decline, the longer-term returns over 1 to 5 years indicate significant growth, particularly in price returns.